Home
About Us
About Us
Industry Recognition
Experts
Milestones
Platforms
SolnAb™
SolnNuc™
SolnZyme™
SolnCell™
SolnMat™
Solutions
Metabolic Disease Therapeutics
Musculoskeletal Regeneration
Regenerative Biomaterials
Smart Health Management
Ecosystem
Ecosystem
Partners
Technologies
Products
News
Contact
Contact
Careers
Message
中文
Position：
Home
>
About Us
>
Milestones
>
2026
2026
All
SolnAb™ antibody platform reached PCC, continuously expanding the antibody drug candidate pool.
2026-07-22
More >>
SolnNuc™ Intelligent Nucleic Acid Drug Development Platform launched, entering the small nucleic acid therapeutics space.
2026-07-22
More >>
SolnZyme™ Enzyme Engineering Platform launched, expanding industrial applications of enzyme preparations.
2026-07-22
More >>
Established strategic partnerships with multiple pharmaceutical companies to advance the translational deployment of small nucleic acid and enzyme optimization technologies.
2026-07-22
More >>
Tendon stem cell drug candidate completed national filing.
2026-07-22
More >>
Launched Longevity Clinic, achieving a closed-loop model of "R&D–Production–Application."
2026-07-27
More >>
National High-Tech Enterprise status pending approval.
2026-07-27
More >>
Class II medical device approval received.
2026-07-27
More >>
1
